Sign in
Taking peoplePhase 3

Customized Antibiotic Treatment Duration Among Hospitalized Patients With Moderately Severe Community-Acquired Pneumonia

Key facts

Who runs it
Assistance Publique - Hôpitaux de Paris
Where
France14 sites in 1 countryChoose a country to see its sites
Status
Recruiting
Phase
Phase 3
People taking part
328 people, planned
Started
5 Feb 2024
Expected to end
May 2027
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Stop antibiotic
  • Continue the antimicrobial treatment
Record updated
20 March 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 24 criteriaShow less

Who can take part

  • Adult patient (≥18 years old)
  • Admitted to hospital for suspected CAP defined by the presence of at least 2 of the following diagnostic clinical criteria:; Fever (temperature > 38°C) or hypothermia (< 36°C); Dyspnea; Cough; Production of purulent sputum; Crackles
  • Radiological evidence of a new infiltrate (chest X-ray or CT scan)
  • Negative viral respiratory testing
  • Treated for a minimum of 48 hours with antibiotics (excluding azithromycin due to its prolonged half-life)Presenting with an early clinical response within the last 24 hours (up to 7 days after the start of antibiotic treatment, if planned treatment duration > 7 days), defined by the presence of all the following criteria:apyrexia (T°C ≤ 37.8)heart rate < 100/minrespiratory rate < 24/min, according to the patient's usual mode of oxygenation,arterial oxygen saturation ≥ 92%, according to the patient's usual mode of oxygenation,Patient currently under antibiotic treatment for his suspected CAP (i.e. the last dose of ATB has been administered to the patient less than 24 hours ago)
  • Patient presenting a clinical response within the last 24 hours defined by the presence of all the following criteria:; apyrexia (T°C ≤ 37.8); heart rate < 100/min; respiratory rate < 24/min, according to the patient's usual mode of oxygenation,; arterial oxygen saturation ≥ 92%, according to the patient's usual mode of oxygenation,; systolic blood pressure ≥ 90mmHg, The last occurring of these criteria must have appeared within the last 24 hours
  • The antibiotic treatment for suspected CAP has started at least 48 hours ago and at most 6 days ago
  • No other site of infection besides respiratory
  • Affiliated to Health insurance
  • Has given informed consent
  • Patient understanding oral and written French, or presence of a relative who can explain and help him complete the study documents

Who cannot take part

  • Any other infection necessitating concomitant antibiotic treatment
  • Concomitant steroid treatment (only for patients treated with fluoroquinolones antibiotics)
  • Pre-existing aortic aneurysm or dissection, family history of aortic aneurysm or dissection, Marfan syndrome, Ehlers-Danlos syndrome, Takayasu arthritis, uncontrolled arterial hypertension, atherosclerosis (only for patients treated with fluoroquinolones antibiotics)
  • Signs of severe CAP (abscess, massive pleural effusion, serious chronic respiratory insufficiency)
  • Known immunosuppression (asplenia, neutropenia, agammaglobulinemia, transplant, myeloma, lymphoma, known HIV and CD4<200/mm3)
  • Suspected or confirmed legionellosis
  • Confirmed or suspected aspiration pneumonia or healthcare-associated pneumonia
  • Treatment of suspected CAP with azithromycin (due to its prolonged half-life)
  • Pregnant or breastfeeding woman
  • Life expectancy < 1 month
  • Patient under legal guardianship (French "tutelle" or "curatelle")
  • Patient without fixed address
  • Patient enrolled in another interventional clinical trial on CAP treatment

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The primary objective of the study is to evaluate if the efficacy of an experimental strategy on antibiotic treatment duration based on stopping treatment when stability criteria are reached after at least 48 h of treatment, is non-inferior to the efficacy of standard antibiotic duration in CAP patients treated in the hospital setting.

Read full original descriptionShow less

As the secondary objectives, the study aims

* To study if the efficacy of our experimental strategy on antibiotic treatment duration compared to standard of care in CAP patients treated in the hospital setting is non-inferior in terms of:

* Persistence of cure at Day 30 of antibiotic treatment * All-cause mortality rate on Day 30 of antibiotic treatment * Patients evolution of pneumonia symptoms and quality of life via 2 scores (CAP score, CAP Sym) at Day 0 of treatment (retrospectively), at stability (Day S), at Day 7 , at Day 15, and at Day 30 of antibiotic treatment. * To compare between the 2 study arms at Day 30 of antibiotic treatment:

* The duration of antibiotic treatment; * The length of hospital stay; * The frequency and severity of adverse events during the 30 days after the start of treatment. * To explore the impact of reduced antibiotic treatment duration for CAP on the oropharyngeal resistome.

The 2 groups in the trial

  • Antibiotic treatmentPlacebo, for comparison

    Antibiotic treatment duration left to the physician's judgment (usual practice: total treatment duration between 5 to 10 days according to French guidelines; more than 7 days of treatment should be justified).

    Treatment: Continue the antimicrobial treatment

  • Interruption of treatmentTreatment being tested

    Interruption of treatment based on the patient reaching all of the following stability criteria (body temperature ≤ 37.8°C; heart rate ≤ 100/min; systolic blood pressure \> 90mmHg; oxygen saturation ≥ 92%; respiratory rate \< 24/min; normal mental status (27)), with a treatment duration no shorter than 48 h.

    Treatment: Stop antibiotic

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Record updated
20 March 2025